桑协世纪
中力控股是国家工信部中小企业发展促进中心“全国中小企业商业与股权研究中心”执行单位和“深圳市企业并购促进会”核心赋能平台,被国家工信部授予国家级中小企业公共服务示范平台。中力控股旗下拥有中力顾问、中力产业、中力鑫达、中力资本、京鹏资本、中力知识科技、中力传播、中力智造、风火轮数字、一股绳科技等运营实体,是集上市培育、专精特新培育、商学咨询、产业链整合、跨区域产业协作、产业数字化平台、产业基金、产业大数据、产教融合为一体的创新型企业/产业服务平台。 中力控股围绕“产业、资本、合伙人”三大核心领域,大力推进产业互联网、上市培育、组织创新三项核心工作。帮助传统产业数字化和资本化转型升级,协同产业链“链长”+“链主”推动区域经济和产业高质量发展。中力控股与深圳、广州、湖北、青岛、重庆等数十个地方政府共建了“专精特新培育基地”、“企业上市培育中心”,联合培育了大批专精特新型中小企业、非上市股份公司,部分企业已经实现了上市或共赢式并购。中力控股高度关注企业创新发展和新时代组织激发,长期为企业提供商业创新、股权激励、合伙型组织、合伙人特训、新生代企业家特训等商学咨询服务。
WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity,foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.